...
首页> 外文期刊>Diabetes/metabolism research and reviews >Encapsulated pancreatic progenitors derived from human embryonic stem cells as a therapy for insulin-dependent diabetes
【24h】

Encapsulated pancreatic progenitors derived from human embryonic stem cells as a therapy for insulin-dependent diabetes

机译:源自人类胚胎干细胞的封装胰腺祖细胞作为胰岛素依赖型糖尿病的治疗方法

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Cellular-based therapies for insulin-dependent diabetes are potential means of achieving and maintaining normal blood glucose levels (BGL) without the need for insulin administration. Islets isolated from donor pancreases have been the most common tissue used to date, but supply is a limiting factor. The use of human embryonic stem cells (hESC) as a therapy became a possibility with the report that these cells could be differentiated to pancreatic progenitors (PP) over 12 days in vitro. Conversion of PP to glucose-responsive insulin-secreting cells can be achieved by transplanting the progenitors in vivo where cell maturation occurs. To date this step has not been shown under in vitro conditions. Methods: Prior to transplanting, cells are encapsulated in alginate to prevent the immune cells of recipient attacking the graft. The alginate capsules have pores with a molecular weight cut-off of 250 kDa. These are too small to allow entry of immune cells, but large enough for passage of nutrients and insulin. Results: Encapsulated insulin-producing cells survive and function when transplanted, and have been shown to normalize BGL when allografted into diabetic mice. As few as 750 encapsulated human islets are sufficient to normalize BGL of diabetic non-obese diabetic severe combined immunodeficient (NOD/SCID) recipient mice for at least 2 months. The safety of transplanting encapsulated human islets as demonstrated by the lack of major adverse events and infection was recently shown in a first-in-human clinical trial. Finally, fetal porcine islet-like cell clusters, which are akin to PP derived from ESC, mature and normalize BGL of diabetic recipient mice with the same efficiency as non-encapsulated clusters placed under the kidney capsule. Conclusion: Transplanting encapsulated PP, derived from hESCs, into diabetic recipients is the strategy that is now being explored in the Australia Diabetes Therapy Project.
机译:用于胰岛素依赖型糖尿病的基于细胞的疗法是实现和维持正常血糖水平(BGL)的潜在手段,而无需注射胰岛素。迄今为止,从供体胰腺中分离出的胰岛是最常见的组织,但是供应是一个限制因素。随着人类胚胎干细胞(hESC)在体外培养12天后可分化为胰腺祖细胞(PP)的报道,这种疗法成为可能。通过将祖细胞移植到体内发生细胞成熟的体内,可以实现PP向葡萄糖反应性胰岛素分泌细胞的转化。迄今为止,尚未在体外条件下显示该步骤。方法:在移植之前,将细胞封装在藻酸盐中,以防止受体的免疫细胞攻击移植物。藻酸盐胶囊具有截留分子量为250kDa的孔。它们太小而不能进入免疫细胞,但足够大,无法通过营养物质和胰岛素。结果:封装的胰岛素产生细胞在移植后可以存活并发挥功能,并且已显示出将其同种异体移植到糖尿病小鼠中可使BGL正常化。少至750个封装的人胰岛足以使糖尿病非肥胖型糖尿病严重合并免疫缺陷(NOD / SCID)受体小鼠的BGL正常化至少2个月。最近在一项首次在人体内的临床试验中证明了缺乏重大不良事件和感染所证明的移植封装的人类胰岛的安全性。最后,类似于源自ESC的PP的胎儿猪胰岛样细胞簇以与置于肾囊下的非包囊簇相同的效率成熟并正常化糖尿病受体小鼠的BGL。结论:将源自hESCs的封装PP移植到糖尿病患者体内是澳大利亚糖尿病治疗项目正在研究的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号